Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2025-5415

Published: 2025

Journal Articles

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）

Bing Chen, Xiaoyan Shao, Yuanyuan Jin, Yong Xu, Qinglin Shi, Chaoyang Guan, Xuxing Shen, Ping Li, Yujie Wu, Hui Zeng, Yu Zhu, Min Zhou, Lei Fan, Yaqiong Lu, Hongyu Gui, Lijuan Chen

Blood (2025) 146 (Supplement 1): 254.

https://doi.org/10.1182/blood-2025-254

Published: 2025

Journal Articles

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Blood (2025) 146 (Supplement 1): 908.

https://doi.org/10.1182/blood-2025-908

Published: 2025

Journal Articles

Single-cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome

Ting Zhang, Xu Shen, Yuanyuan Jin, Xin Cheng, Yuan Xia, Jianyong Li, Lijuan Chen

Blood (2025) 146 (Supplement 1): 2144.

https://doi.org/10.1182/blood-2025-2144

Published: 2025

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis

Lijuan Chen, Yongsheng Wang, Jie Wang, Linyu Yang, Ting Niu

Blood (2024) 144 (Supplement 1): 486.

https://doi.org/10.1182/blood-2024-210674

Published: 2024

Journal Articles

Tigit: The Potential Mechanisms of Relapse in Multiple Myeloma Following Anti-BCMA CAR-T Therapy and a Promising Target for Improving CAR-T Efficacy

Yuan Xia, Xuxing Shen, Min Shi, Na Shen, Yu Zhu, Lei Fan, Jianyong Li, Lijuan Chen

Blood (2024) 144 (Supplement 1): 2033.

https://doi.org/10.1182/blood-2024-205126

Published: 2024

Journal Articles

Combination of Geriatric Assessment and Clinical Factors to Predict the Survival of Elderly Patients with Myeloma

Yuanyuan Jin, Ruoru Liu, Jianyong Li, Lei Fan, Lijuan Chen

Blood (2024) 144 (Supplement 1): 6951.

https://doi.org/10.1182/blood-2024-204360

Published: 2024

Journal Articles

Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD)

Yuanyuan Jin, Xuezhong Zhang, Jianyong Li, Lei Fan, Lijuan Chen

Blood (2024) 144 (Supplement 1): 7080.

https://doi.org/10.1182/blood-2024-201203

Published: 2024

Journal Articles

Effect of Sarcopenia and Nutritional Risk Factors in Patients with Multiple Myeloma

Xuxing Shen, Jiapei Yu, Xin Cheng, Ye Yao, Yuan Jin, Qinglin Shi, Jianyong Li, Lijuan Chen

Blood (2024) 144 (Supplement 1): 6909.

https://doi.org/10.1182/blood-2024-199530

Published: 2024

Journal Articles

Survival Trends and Prognostic Factors of Patients with Newly Diagnosed Multiple Myeloma Accompanied with Extramedullary Disease

Jing Wang, Na Shen, Xuxing Shen, Run Zhang, Yuan Jin, Jianyong Li, Lijuan Chen

Blood (2023) 142 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2023-178373

Published: 2023

Journal Articles

Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD): A Prospective, Open-Label, Multicenter, Phase 2 Study

Yuanyuan Jin, Jianyong Li, Lijuan Chen

Blood (2023) 142 (Supplement 1): 6729.

https://doi.org/10.1182/blood-2023-179890

Published: 2023

Journal Articles

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

Weijun Fu, Juan Du, Lu Zhong, Lijuan Chen, Jian Li, Donghua Zhang, Jianqing Mi, Yan Liu, Sheng Wu, Richard Labotka, Cong Li, Wenhan Jiang, Wenming Chen

Blood (2023) 142 (Supplement 1): 6735.

https://doi.org/10.1182/blood-2023-181444

Published: 2023

Journal Articles

Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up

Jian-Qing Mi, Wanhong Zhao, Hongmei Jing, Weijun Fu, Jianda Hu, Lijuan Chen, Yiwen Zhang, Dan Yao, Hui Li, Jordan M Schecter, Fan Yang, Huabin Sun, Sen Hong Zhuang, Da Xu, Tracy Luo, Xiaohu Fan, Ting Niu, Jie Jin, Sai-Juan Chen

Blood (2022) 140 (Supplement 1): 7542–7544.

https://doi.org/10.1182/blood-2022-159185

Published: 2022

Journal Articles

Phase 1 Safety and Dose Escalation of Purinostat Mesylate, a Uniquely Potent and Selective Inhibitor of HDAC I and IIb in Relapsed or Refractory Lymphoma and Multiple Myeloma

Jie Wang, He Li, Linyu Yang, Ailin Zhao, Peng Zhao, Jishi Wang, Jin Xiang, Jia Miao, Li Zheng, Yongsheng Wang, Lijuan Chen, Ting Niu

Blood (2022) 140 (Supplement 1): 6612–6613.

https://doi.org/10.1182/blood-2022-167079

Published: 2022

Journal Articles

Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma

Yuan Xia, Run Zhang, Yuanyuan Jin, Qinglin Shi, Yujie Wu, Jianyong Li, Lijuan Chen

Blood (2022) 140 (Supplement 1): 10015–10016.

https://doi.org/10.1182/blood-2022-166622

Published: 2022

Journal Articles

Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone

Ailin Zhao, Xin Wang, Mengshi Hu, Lijuan Chen, Ting Niu

Blood (2022) 140 (Supplement 1): 2624–2625.

https://doi.org/10.1182/blood-2022-169258

Published: 2022

Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Blood (2021) 138 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2021-145282

Published: 2021

Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Blood (2021) 138 (Supplement 1): 4778.

https://doi.org/10.1182/blood-2021-146784

Published: 2021

Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 547.

https://doi.org/10.1182/blood-2021-152576

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Efficacy and safety of a fully human BCMA CAR T-cell therapy for high-risk newly diagnosed transplant-ineligible multiple myeloma: Updated results from an open label, single-arm，phase 1 study（fumanba-2）

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Single-cell analysis identifies a KLF5–Neutrophil–Plasma cell axis driving immune suppression in POEMS syndrome

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

First-in-Human Phase I/IIa Safety and Efficacy of Flonoltinib Maleate, a New Generation of JAK2/FLT3 Inhibitor in Myelofibrosis

Tigit: The Potential Mechanisms of Relapse in Multiple Myeloma Following Anti-BCMA CAR-T Therapy and a Promising Target for Improving CAR-T Efficacy

Combination of Geriatric Assessment and Clinical Factors to Predict the Survival of Elderly Patients with Myeloma

Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD)

Effect of Sarcopenia and Nutritional Risk Factors in Patients with Multiple Myeloma

Survival Trends and Prognostic Factors of Patients with Newly Diagnosed Multiple Myeloma Accompanied with Extramedullary Disease

Response and Safety of Selinexor with VRD Regimen in Newly Diagnosed Multiple Myeloma (NDMM) with Extramedullary Disease (EMD): A Prospective, Open-Label, Multicenter, Phase 2 Study

Ixazomib Maintenance Therapy in Chinese Patients with Newly Diagnosed Multiple Myeloma Not Treated with Stem Cell Transplantation: A Single-Arm, Open-Label Study

Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up

Phase 1 Safety and Dose Escalation of Purinostat Mesylate, a Uniquely Potent and Selective Inhibitor of HDAC I and IIb in Relapsed or Refractory Lymphoma and Multiple Myeloma

Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma

Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only